FDA Archives - Page 20 of 24 - ��ýҕ�l Health News

Podcast: KHN’s ‘What The Health?’ New Year, New Health Proposals

Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”

Jan. 10, 2019

Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment

Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.

By Liz Szabo

Jan. 8, 2019

Tainted Drugs

When Medicine Makes Patients Sicker

The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.

By Sydney Lupkin

Jan. 4, 2019

How The Government Shutdown Affects Health Programs

Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.

By Shefali Luthra

Jan. 3, 2019

5 Ways Nixing The Affordable Care Act Could Upend The Entire Health System

There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.

By Julie Rovner

Dec. 20, 2018

Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs

Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.

By Sarah Jane Tribble

Dec. 20, 2018

In Grandma’s Stocking: An Apple Watch To Monitor Falls, Track Heart Rhythms

The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Apple’s target audience beyond the usual, tech-savvy, early adopters to those with older tickers.

By Rachel Bluth

Dec. 4, 2018

The Orphan Drug Machine

Government Investigation Finds Flaws In the FDA’s Orphan Drug Program

A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.

By Sarah Jane Tribble and Sydney Lupkin

Nov. 30, 2018

Must-Reads Of The Week From Brianna Labuskes

Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.

By Brianna Labuskes

Nov. 30, 2018

Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake

In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”

Nov. 29, 2018

Podcast: KHN’s ‘What The Health?’ Health Nerd Books For The Holidays

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a “Medicare-for-all” bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.

Nov. 20, 2018

Fish Oil Drug Looks Heart-Healthy. Just Don’t Swallow It Hook, Line And Sinker.

The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.

By Shefali Luthra

Nov. 20, 2018

Must-Reads Of The Week From Brianna Labuskes

Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.

By Brianna Labuskes

Nov. 16, 2018

Heart Drug Spotlights Troubling Trends In Drug Marketing

Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.

By Shefali Luthra

Nov. 2, 2018

Hidden Drugs And Danger Lurk In Over-The-Counter Supplements, Study Finds

Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.

By Rachel Bluth

Oct. 12, 2018

Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions

In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.

Oct. 11, 2018

The Feds’ Termination Of A Tiny Contract Inflames Bitter Fight Over Fetal Tissue

Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.

By Emmarie Huetteman

Oct. 8, 2018

Podcast: KHN’s ‘What The Health?’ Some Things Old, Some Things New

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.

Oct. 4, 2018

Drugmakers Play The Patent Game To Lock In Prices, Block Competitors

Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.

By Sarah Jane Tribble

Oct. 2, 2018